Pharming Group N.V.
PHAR
$8.51
-$0.07-0.82%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 245.32M | 218.72M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | 245.32M | 218.72M | |
| Cost of Revenue | -- | -- | 25.21M | 24.37M | |
| Gross Profit | -- | -- | 220.10M | 194.35M | |
| SG&A Expenses | -- | -- | 175.26M | 160.16M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | 19.01M | 11.59M | |
| Total Operating Expenses | -- | -- | 288.15M | 264.30M | |
| Operating Income | -- | -- | -42.83M | -45.58M | |
| Income Before Tax | -- | -- | -12.01M | -28.06M | |
| Income Tax Expenses | -- | -- | -1.46M | -6.01M | |
| Earnings from Continuing Operations | -- | -- | -10.55 | -22.06 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -10.55M | -22.06M | |
| EBIT | -- | -- | -42.83M | -45.58M | |
| EBITDA | -- | -- | -28.71M | -32.05M | |
| EPS Basic | -- | -- | -0.02 | -0.04 | |
| Normalized Basic EPS | -- | -- | -0.03 | -0.04 | |
| EPS Diluted | -- | -- | -0.02 | -0.04 | |
| Normalized Diluted EPS | -- | -- | -0.03 | -0.04 | |
| Average Basic Shares Outstanding | -- | -- | 2.68B | 2.63B | |
| Average Diluted Shares Outstanding | -- | -- | 2.68B | 2.63B | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |